Literature DB >> 12364656

Behçet's syndrome: response to infliximab after failure of etanercept.

C Estrach, S Mpofu, R J Moots.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12364656

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  7 in total

Review 1.  Targeted biologic approaches to the treatment of systemic vasculitis.

Authors:  Andreea Coca; Jennifer H Anolik
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

2.  Behcet's disease.

Authors:  Jagdish R Nair; Robert J Moots
Journal:  Clin Med (Lond)       Date:  2017-02       Impact factor: 2.659

3.  Mimicry and deception in inflammatory bowel disease and intestinal behçet disease.

Authors:  Erika L Grigg; Sunanda Kane; Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-02

4.  Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.

Authors:  Salvatore Gulli; Carlo Arrigo; Loredana Bocchino; Lucia Morgante; Donatella Sangari; Irene Castagna; Gian Filippo Bagnato
Journal:  BMC Musculoskelet Disord       Date:  2003-08-28       Impact factor: 2.362

5.  Behçet's syndrome treated with infliximab, which caused a palmoplantar pustulosis, subsequently maintained on low-dose etanercept.

Authors:  Amani Tresh; Victoria H Smith; Richard A G Parslew
Journal:  Libyan J Med       Date:  2012-10-11       Impact factor: 1.657

Review 6.  Cytokines and Biologics in non-infectious autoimmune uveitis: bench to bedside.

Authors:  Rupesh Agrawal; Jayant Iyer; John Connolly; Daiju Iwata; Stephen Teoh
Journal:  Indian J Ophthalmol       Date:  2014-01       Impact factor: 1.848

Review 7.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.